1,3-dimethyl-4-[3-[(3S)-pyrrolidin-3-yl]oxyanilino]pyrazolo[3,4-b]pyridine-5-carboxamide | 389058-61-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1,3-dimethyl-4-[3-[(3S)-pyrrolidin-3-yl]oxyanilino]pyrazolo[3,4-b]pyridine-5-carboxamide
• CAS: 389058-61-1
• 化学式: C₁₉H₂₂N₆O₂
• 分子量: 366.423
• InChiKey: APLFIOYOMOMQCQ-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 1,3-dimethyl-4-[3-[(3S)-pyrrolidin-3-yl]oxyanilino]pyrazolo[3,4-b]pyridine-5-carboxamide 在 吡啶 作用下， 反应 15.0h， 以100%的产率得到4-[3-[(3S)-1-acetylpyrrolidin-3-yl]oxyanilino]-1,3-dimethylpyrazolo[3,4-b]pyridine-5-carboxamide
  参考文献：
  名称：

  New orally active PDE4 inhibitors with therapeutic potential

  摘要：

  The design synthesis, and biological evaluation of a series of pyrazolopyridines was carried out. Structural optimization of the aniline moiety of 4-anilinopyrazolopyridinc derivative 3a, which is one of the newly discovered chemical leads for PDE4 inhibitors from our in-house library, was performed successfully. The details of the discovery of new orally active PDE4 inhibitors, which are expected to show therapeutic potential, are presented and their structure-activity relationships are discussed. Pharmacological evaluation and pharmacokinetic data for representative compounds are also presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.032
• 作为产物：
  描述：

  间硝基苯酚 在 palladium on activated charcoal 盐酸 、 氢气 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙酸乙酯 为溶剂， 反应 19.0h， 生成 1,3-dimethyl-4-[3-[(3S)-pyrrolidin-3-yl]oxyanilino]pyrazolo[3,4-b]pyridine-5-carboxamide
  参考文献：
  名称：

  New orally active PDE4 inhibitors with therapeutic potential

  摘要：

  The design synthesis, and biological evaluation of a series of pyrazolopyridines was carried out. Structural optimization of the aniline moiety of 4-anilinopyrazolopyridinc derivative 3a, which is one of the newly discovered chemical leads for PDE4 inhibitors from our in-house library, was performed successfully. The details of the discovery of new orally active PDE4 inhibitors, which are expected to show therapeutic potential, are presented and their structure-activity relationships are discussed. Pharmacological evaluation and pharmacokinetic data for representative compounds are also presented. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.032